8-KOther EventsExhibits & Filings

STRYKER CORP 8-K Report, Corporate Update (Dec 12, 2014)

Filed December 12, 2014For Securities:SYK

Summary

Stryker Corporation has entered into a settlement with the U.S. Department of Justice (DOJ) concerning investigations into the sales and marketing practices of the OtisKnee prior to its acquisition of OtisMed in November 2009. This filing serves to formally report this significant event, which was also announced via a press release on December 8, 2014. While the specifics of the settlement are not detailed in this 8-K, its resolution marks an important step in addressing legacy legal and compliance issues related to a past acquisition. Investors should view this settlement as a conclusion to a previously disclosed, ongoing investigation. The financial implications and any potential impact on future operations are crucial areas for investors to monitor as more details of the settlement are likely to emerge. This event underscores the importance of due diligence and post-acquisition integration, particularly concerning the compliance and regulatory landscape of acquired entities.

Key Highlights

  • 1Stryker Corp. settled with the U.S. Department of Justice (DOJ) on December 8, 2014.
  • 2The settlement pertains to civil and criminal investigations related to the OtisKnee product.
  • 3The investigations focused on sales and marketing practices prior to Stryker's acquisition of OtisMed in November 2009.
  • 4The company issued a press release on December 8, 2014, announcing the settlement.
  • 5This filing (8-K) formally reports the event and includes the press release as an exhibit.

Frequently Asked Questions

The DOJ investigation focused on the sales and marketing practices of the OtisKnee product before Stryker acquired OtisMed in November 2009. This included both civil and criminal aspects.

This 8-K filing does not disclose the specific financial terms or penalties associated with the settlement. Investors would need to refer to the press release (Exhibit 99.1) or future filings for potential details.

The settlement resolves a previously disclosed, ongoing investigation, which can be viewed positively as it removes a layer of uncertainty. However, investors should assess any financial penalties or ongoing compliance requirements that may arise from the settlement and consider their potential impact on the company's financial performance and reputation.

Stryker Corporation acquired OtisMed in November 2009.